Stem definition | Drug id | CAS RN |
---|---|---|
tyrosine kinase inhibitors | 5680 | 1448169-71-8 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
July 4, 2023 | EMA | TAIHO PHARMA NETHERLANDS B.V. | |
Sept. 30, 2022 | FDA | TAIHO ONCOLOGY |
None
None
None
None
Source | Code | Description |
---|---|---|
ATC | L01EN04 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors |
MeSH PA | D000970 | Antineoplastic Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Intrahepatic cholangiocarcinoma | indication | 109842005 | DOID:4928 |
None
None
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
4MG | LYTGOBI | TAIHO ONCOLOGY | N214801 | Sept. 30, 2022 | RX | TABLET | ORAL | 9108973 | Feb. 23, 2033 | METHOD OF TREATING INTRAHEPATIC CHOLANGIOCARCINOMA |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
4MG | LYTGOBI | TAIHO ONCOLOGY | N214801 | Sept. 30, 2022 | RX | TABLET | ORAL | Sept. 30, 2027 | NEW CHEMICAL ENTITY |
4MG | LYTGOBI | TAIHO ONCOLOGY | N214801 | Sept. 30, 2022 | RX | TABLET | ORAL | Sept. 30, 2029 | TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC INTRAHEPATIC CHOLANGIOCARCINOMA HARBORING FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) GENE FUSIONS OR OTHER REARRANGEMENTS |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Fibroblast growth factor receptor 3 | Kinase | INHIBITOR | IC50 | 8.79 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Fibroblast growth factor receptor 1 | Kinase | INHIBITOR | IC50 | 8.74 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Fibroblast growth factor receptor 2 | Kinase | INHIBITOR | IC50 | 8.85 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Fibroblast growth factor receptor 4 | Kinase | INHIBITOR | IC50 | 8.79 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Tyrosine-protein kinase BTK | Kinase | IC50 | 7.02 | CHEMBL |
ID | Source |
---|---|
TAW | PDB_CHEM_ID |
CHEMBL3701238 | ChEMBL_ID |
C000713257 | MESH_SUPPLEMENTAL_RECORD_UI |
9786 | IUPHAR_LIGAND_ID |
DB15149 | DRUGBANK_ID |
019197 | NDDF |
4041794 | VANDF |
C5139845 | UMLSCUI |
10879 | INN_ID |
D11725 | KEGG_DRUG |
71621331 | PUBCHEM_CID |
2628190 | RXNORM |
361969 | MMSL |
40947 | MMSL |
d09927 | MMSL |
4B93MGE4AL | UNII |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
LYTGOBI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64842-0120 | TABLET | 4 mg | ORAL | NDA | 27 sections |